Business
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s web
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"image","alt":"Lexicon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Lexicon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bhkXAP8bO_Q1Z4PDGMz_0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8","width":166,"height":50}},"lazy":false},{"type":"text","content":"THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.","length":399,"tagName":"p"},{"type":"text","content":"Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.","length":338,"tagName":"p"},{"type":"text","content":"About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications.","length":367,"tagName":"p"},{"type":"text","content":"For Investor and Media Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. [email protected]","length":128,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]